The first second-generation adenosine drug enters the US market

Journal article

Open access

Peer reviewed

Amir Pelleg and Luiz Belardinelli

Purinergic signalling, v 4(4), pp 407-408

01 Dec 2008

PMID: 18566916

Files and links (2)

url

https://link.springer.com/content/pdf/10.1007%2Fs11302-008-9114-2.pdfView

Published, Version of Record (VoR) Open

url

https://doi.org/10.1007/s11302-008-9114-2View

Published, Version of Record (VoR) Open

Biochemistry & Molecular Biology

Life Sciences & Biomedicine

Neurosciences

Neurosciences & Neurology

Science & Technology

7 Record Views

5 citations in Scopus

Title: The first second-generation adenosine drug enters the US market
Creators: Amir Pelleg - Drexel University
Luiz Belardinelli - CV Therapeutics, Inc.
Publication Details: Purinergic signalling, v 4(4), pp 407-408
Publisher: Springer Nature
Number of pages: 2
Resource Type: Journal article
Language: English
Web of Science ID: WOS:000260966900013
Scopus ID: 2-s2.0-56549120785
Other Identifier: 991019348754304721

This publication has contributed to the advancement of the following goals:

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types: Industry collaboration; Domestic collaboration
Web of Science research areas: Biochemistry & Molecular Biology; Neurosciences